Central European Journal of Medicine

, Volume 8, Issue 3, pp 310–316 | Cite as

Detection of presensitization in recipients of kidney transplants

  • Nada G. Vasić
  • Svetlana I. Vojvodić
  • Dušica S. Ademović-Sazdanić
Research Article
  • 44 Downloads

Abstract

Objective

The preformed antibodies detection in potential kidney recipients is necessary in pretransplant evaluation. The aim of this study was to determine the correlation between the application of blood transfusions and sensitization level in potential kidney transplants.

Methods

The study included 268 potential kidney transplants from the region of Vojvodina. The presence of preformed antibodies was tested by microlymphocitotoxicity test. Pearson’s correlation coefficient was applied to determine the influence of three variables on sensitization level: number and volume of transfused blood units and time elapsed from last transfused unit.

Results

Of 268 eligible patients, 206 patients had a history of blood transfusion. Results of the study showed that the application of great number and volume of transfused units increased the sensitization level (correlation coefficients were r = +0,283 and r = +0,235, respectively) with statistical significance as well as the negative correlation between the time elapsed from the last transfusion and the degree of sensitization (r = −0,082) with no statistical significance.

Conclusion

Our study revealed that there is a stronger positive correlation between the number of received blood units than the volume of received blood products and the level of preformed antibodies.

Keywords

Anti-HLA antibodies Preformed antibodies Kidney transplantation Sensitization 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Cecka JM., The OPTN/UNOS renal transplant registry, Clin. Transplant., 2005, 1–16Google Scholar
  2. [2]
    Cecka JM., The OPTN/UNOS Renal Transplant Registry, Clin. Transplant., 2004, 1–16Google Scholar
  3. [3]
    Amico P., Evolution of graft survival in kidney transplantation: an analysis of the OPTN/UNOS Renal Transplant Registry, Clin. Transplant., 2010, 1–15Google Scholar
  4. [4]
    Garcia-Garcia G., Harden P., Chapman J., For the world kidney day steering committee 2012., The global role of kidney transplantation, Nephrology., 2012, 17, 199–203PubMedCrossRefGoogle Scholar
  5. [5]
    Persijn GG., Allocation of organs, particularly kidneys, within Eurotransplant, Hum. Immunol., 2006, 67, 419–423Google Scholar
  6. [6]
    Mayer G., Persijn GG., Eurotransplant kidney allocation system (ETKAS): rationale and implementation, Nephrol. Dial. Transpl., 2006, 21, 2–3CrossRefGoogle Scholar
  7. [7]
    Hardy S., Lee SH., Terasaki PI., Sensitization 2001, Clin. Transplant., 2001, 271Google Scholar
  8. [8]
    Peng A., Vo A., Jordan SC., Transplantation of the highly human leukocyte antigen-sensitized patient: Long-term outcomes and future directions, Transplant. Rev., 2006, 20, 46CrossRefGoogle Scholar
  9. [9]
    Warren DS., Montgomery RA., Incompatible kidney transplantation: Lessons from a decade of desensitization and paired kidney exchange, Immunol. Res. 2010, 47, 257PubMedCrossRefGoogle Scholar
  10. [10]
    Eikmans M., Waanders MM., Roelen DL., van Miert PP., Anholts JD., de Fijter HW., et al., Differential effect of pretransplant blood transfusions on immune effector and regulatory compartments in HLA-sensitized and nonsensitized recipients, Transplantation., 2010, 90, 1192–1199PubMedCrossRefGoogle Scholar
  11. [11]
    Nicol D., MacDonald AS., Lawen J., Belitsky P., Early prediction of renal allograft loss beyond one year, Transpl. Int., 1993, 6, 153–157PubMedCrossRefGoogle Scholar
  12. [12]
    Stanković B., Taseski J., Balint B., Trkuljić M., Veljančić V., Hrvačević R., et al., Značaj transfuzija krvi za razvoj citotoksičnih antitela kod bolesnika na hemodijalizi, Vojnosanit. Pregl., 2000, 57, 37–41PubMedGoogle Scholar
  13. [13]
    Balasubramaniam GS., Morris M., Gupta A., Mesa IR., Thuraisingham R., Ashman N., Allosensitization Rate of Male Patients Awaiting First Kidney Grafts After Leuko-Depleted Blood Transfusion, Transplantation., 2012, 93, 418–422PubMedCrossRefGoogle Scholar
  14. [14]
    Vaidya S., Synthesis of new and memory HLA antibodies from acute and chronic rejections versus pregnancies and blood transfusions, Transplant. P., 2005, 37, 648–649CrossRefGoogle Scholar
  15. [15]
    Scornik JC., Ireland JE., Howard RJ., Pfaff WW., Assessment of the risk for broad sensitization by blood transfusions, Transplantation., 1984, 37, 249PubMedCrossRefGoogle Scholar
  16. [16]
    Sheldon S., Poulton K., HLA Typing and Its Influence on Organ Transplantation, Methods. Mol. Biol., 2006, 333, 157–174PubMedGoogle Scholar
  17. [17]
    Petz B., Osnovne statističke metode, Zagreb: Izdanja škole narodnog zdravlja “Andrija Štampar”, 1964, 111–133Google Scholar
  18. [18]
    Morales-Buenrostro LE., Terasaki PI., Marino-Va’zquez LA., et al., “Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males, Transplantation., 2008, 86, 1111PubMedCrossRefGoogle Scholar
  19. [19]
    Susal C., Dohler B., Sadeghi M., et al., HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: A collaborative transplant study report, Transplantation., 2009, 87, 1367PubMedCrossRefGoogle Scholar
  20. [20]
    Terasaki PI., Cai J., Human leukocyte antigen antibodies and chronic rejection: From association to causation, Transplantation., 2008, 86, 377PubMedCrossRefGoogle Scholar
  21. [21]
    Cecka JM., Zhang Q., Reed EF., Preformed cytotoxic antibodies in potential allograft recipients: recent data, Hum. Immunol., 2005, 66, 343–349PubMedCrossRefGoogle Scholar
  22. [22]
    Wolfe RA., Ashby VB., Milford EL., et al., Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, New. Engl. J. Med., 1999, 341, 1725PubMedCrossRefGoogle Scholar
  23. [23]
    Katznelson S., Bhaduri S., Cecka JM., Clinical aspects of sensitization, Clin. Transplant., 1997, 285–296Google Scholar
  24. [24]
    Hrvačević R., et al., Predijalizna transplantacija bubrega, Vojnosanit. Pregl., 2002, 59, 423–427PubMedCrossRefGoogle Scholar
  25. [25]
    Sanfilippo FP., Bollinger RR., MacQueen JM., Brooks BJ., Koepke JA., A randomized study comparing leukocyte-depleted versus packed red cell transfusions in prospective cadaver renal allograft recipients, Transfusion., 1985, 25, 116–119PubMedCrossRefGoogle Scholar
  26. [26]
    Karpinski M., Pochinco D., Dembinski I., Laidlaw W., Zacharias J., Nickerson P., Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates, J. Am. Soc. Nephrol., 2004, 15, 818–824PubMedCrossRefGoogle Scholar
  27. [27]
    Vamvakas EC., Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions, Transfus. Med. Rev., 1998, 12, 258–270PubMedCrossRefGoogle Scholar
  28. [28]
    Scornik JC., Meier-Kriesche H-U., Blood Transfusions in Organ Transplant Patients: Mechanisms of Sensitization and Implications for Prevention, Am. J. Transplant., 2011, 11, 1785–1791PubMedCrossRefGoogle Scholar
  29. [29]
    Bilgin YM., van de Watering LM., Brand A., Clinical effects of leucoreduction of blood transfusions, Neth. J. Med., 2011, 69(10), 441–450PubMedGoogle Scholar
  30. [30]
    Marfo K., Lu A., Ling M., Akalin E., Desensitization protocols and their outcome, Clin. J. Am. Soc. Nephro., 2011, 6, 922–936CrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Nada G. Vasić
    • 1
  • Svetlana I. Vojvodić
    • 2
  • Dušica S. Ademović-Sazdanić
    • 2
  1. 1.General Hospital “Đorđe Joanović”, ZrenjaninZrenjaninSerbia
  2. 2.Institute for Blood Transfusion of VojvodinaNovi SadSerbia

Personalised recommendations